Marshall Wace, LLP’s Alnylam Pharmaceuticals Inc Position
Does Marshall Wace, LLP own Alnylam Pharmaceuticals Inc (ALNY)? Yes — 1.10M shares worth $364M (+0.36% of its 13F portfolio) as of Q1 2026, up from 549.9K shares the prior filed quarter.
Position Value
$364M
Q1 2026
Shares
1.10M
% of Portfolio
+0.36%
Quarters Held
13
currently held
Position History ALNY
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 1.10M | $364M | +0.36% |
| Q4 2025 | 549.9K | $219M | +0.20% |
| Q3 2025 | 508.4K | $232M | +0.24% |
| Q2 2025 | 238.6K | $78M | +0.09% |
| Q1 2025 | 268.9K | $73M | +0.09% |
| Q4 2024 | 378.6K | $89M | +0.11% |
| Q3 2024 | 63.5K | $17M | +0.02% |
| Q4 2023 | 1.3K | $248,833 | 0.00% |
| Q2 2023 | 11.1K | $2M | 0.00% |
| Q2 2022 | 165.3K | $24M | +0.05% |
| Q3 2021 | 16.4K | $3M | +0.01% |
| Q2 2020 | 58.2K | $9M | +0.06% |
| Q2 2019 | 234.5K | $17M | +0.14% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Marshall Wace, LLP’s full portfolio or all institutional holders of ALNY.